Barclays
IRD icon

Barclays’s Opus Genetics IRD Stock Holding History

Barclays’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$156K Buy
32,160
+18,803
+141% +$78.1K ﹤0.01% 4105
2026
Q2 		$54.9K Buy
13,357
+11,457
+603% +$53.4K ﹤0.01% 4293
2026
Q1 		$8.64K Hold
1,900
– – ﹤0.01% 4718
2025
Q4 		$3.82K Hold
1,900
– – ﹤0.01% 5006
2025
Q3 		$3.14K Hold
1,900
– – ﹤0.01% 5123
2025
Q2 		$1.79K Hold
1,900
– – ﹤0.01% 5043
2025
Q1 		$1.86K Buy
+1,900
New +$2.12K ﹤0.01% 4999
2024
Q4 		– Sell
-1,900
Closed -$2.49K – 5535
2024
Q3 		$2.49K Buy
+1,900
New +$2.92K ﹤0.01% 5069

Other funds holding IRD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Texas Capital Bank Wealth Management Services
Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's IRD Position: Q3 2026 in Review

Barclays increased its Opus Genetics (IRD) stake by 141% in Q3 2026, buying an estimated $78.1K and bringing the position to 32,160 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #4105.

Barclays first reported a position in IRD in Q3 2024 and has held it in 8 quarters since. 41 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • Barclays held 32,160 shares of Opus Genetics worth $156K as of Q3 2026.
  • Barclays bought 18,803 Opus Genetics shares in Q3 2026, an estimated $78.1K.
  • Opus Genetics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4105 holding.
  • Barclays first reported a position in Opus Genetics in Q3 2024 and has held it in 8 quarters since.
  • 41 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.